Trial · NCT05384938
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs | Benralizumab | Participants with at least one AE (including SAEs) | 44 | Participants | |
| Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs | Benralizumab | Participants with at least one serious AE | 5 | Participants | |
| Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs | Benralizumab | Participants with at least one treatment-emergent AE (including SAEs) | 43 | Participants | |
| Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs | Benralizumab | Participants with at least one non-treatment-emergent and non-serious AE | 1 | Participants | |
| Severity of AEs | Benralizumab | Participants with at least one mild AE | 33 | Participants | |
| Severity of AEs | Benralizumab | Participants with at least one moderate AE | 16 | Participants | |
| Severity of AEs | Benralizumab | Participants with at least one severe AE | 1 | Participants | |
| Participants With AEs That Led to Study Treatment Discontinuations or Modifications | Benralizumab | 0 | Participants | ||
| Time to First Asthma Exacerbation | Benralizumab | 112.6 | Standard Deviation 50.45 | days | |
| Exacerbation Rate: Before and After Treatment | Benralizumab | Exacerbation before study | 2.0 | Standard Deviation 0.00 | exacerbations events/year |
| Exacerbation Rate: Before and After Treatment | Benralizumab | Exacerbation at end of study | 0.2 | Standard Deviation 0.47 | exacerbations events/year |
| Annualized Exacerbation Rate: Overall | Benralizumab | 0.36 | exacerbation events/year | ||
| Overall Investigators Assessment | Benralizumab | Well controlled | 83 | 52.72 to 69.72 | Participants |
| Overall Investigators Assessment | Benralizumab | Partly controlled | 45 | 25.46 to 41.96 | Participants |
| Overall Investigators Assessment | Benralizumab | Uncontrolled | 7 | 2.11 to 10.39 | Participants |
| Change in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24 | Benralizumab | Week 4 (Visit 2) | -511 | Standard Deviation 779.13 | cells/mm^3 |
| Change in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24 | Benralizumab | Week 16 (Visit 4) | -546 | Standard Deviation 867.79 | cells/mm^3 |
| Change in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24 | Benralizumab | Week 24 (Visit 5) | -541 | Standard Deviation 893.62 | cells/mm^3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05384938/results